Macrophage Migration Inhibitory Factor (MIF) Gene Polymorphism of Urothelial Carcinoma Patients in Iraq

Bladder cancer is the 2nd most frequent malignancy of the genitourinary tract and the fourth most common cancer in men . This study was designed to shed light on the association between polymorphism of macrophage migration inhibitory factor (MIF) gene at -173 locus as risk factor of bladder cancer in Iraqi population by PCR-RFLP. In a hospital-based case-control study of 70 patients with bladder cancer and 30 cancer-free controls frequency-matched by age, sex, smoking status, and alcohol use, we genotyped the MIF polymorphism and analyzed immunohistochemical stained operational bladder cancer tissue sections for MIF. We found that individuals with GC/GG genotype had a significantly decreased risk of bladder cancer ( OR = 1.55, 95% CI, 0.498 to 8.85) than those with CC genotype. The frequencies of the C allele on the MIF gene were significantly increased in Urinary bladder carcinoma patients. MIF -173G>C polymorphism may play a role in the etiology of bladder cancer in Iraqi.